TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Rating of “Buy” from Brokerages

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has earned a consensus recommendation of “Buy” from the ten research firms that are covering the firm, Marketbeat reports. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $11.56.

A number of research analysts have recently weighed in on the company. Cantor Fitzgerald started coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They set an “overweight” rating and a $10.00 price target on the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a report on Friday. Lake Street Capital started coverage on shares of TriSalus Life Sciences in a report on Thursday, February 13th. They set a “buy” rating and a $10.00 price target for the company. Finally, Roth Mkm reiterated a “buy” rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday, January 24th.

TriSalus Life Sciences Trading Down 1.8 %

TLSI stock opened at $5.52 on Tuesday. TriSalus Life Sciences has a one year low of $3.50 and a one year high of $10.42. The firm has a 50-day moving average of $5.42 and a two-hundred day moving average of $4.74. The firm has a market capitalization of $168.32 million, a PE ratio of -2.22 and a beta of 0.48.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.35) EPS for the quarter, hitting analysts’ consensus estimates of ($0.35). The firm had revenue of $8.26 million during the quarter, compared to analyst estimates of $8.12 million. On average, equities research analysts anticipate that TriSalus Life Sciences will post -1.55 earnings per share for the current year.

Insider Activity at TriSalus Life Sciences

In related news, CFO James Emmett Young acquired 24,000 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The shares were acquired at an average cost of $5.40 per share, with a total value of $129,600.00. Following the purchase, the chief financial officer now owns 24,000 shares of the company’s stock, valued at approximately $129,600. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Mary T. Szela bought 4,826 shares of the firm’s stock in a transaction on Monday, January 27th. The shares were bought at an average cost of $5.42 per share, with a total value of $26,156.92. Following the transaction, the chief executive officer now directly owns 429,503 shares of the company’s stock, valued at approximately $2,327,906.26. This trade represents a 1.14 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 54,856 shares of company stock valued at $294,608. Insiders own 32.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TLSI. Geode Capital Management LLC boosted its holdings in TriSalus Life Sciences by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 204,137 shares of the company’s stock valued at $1,023,000 after acquiring an additional 3,710 shares during the period. Northern Trust Corp lifted its position in shares of TriSalus Life Sciences by 22.7% during the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock worth $161,000 after purchasing an additional 5,936 shares during the last quarter. Renaissance Technologies LLC bought a new stake in TriSalus Life Sciences during the 4th quarter valued at approximately $67,000. Walleye Capital LLC acquired a new stake in TriSalus Life Sciences in the 3rd quarter valued at approximately $66,000. Finally, Virtu Financial LLC bought a new position in TriSalus Life Sciences during the third quarter worth $92,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.